{
    "clinical_study": {
        "@rank": "124244", 
        "arm_group": {
            "arm_group_label": "Treatment (dalantercept)", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive dalantercept SC on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity."
        }, 
        "brief_summary": {
            "textblock": "This phase II trial studies the side effects and how well dalantercept works in treating\n      patients with recurrent ovarian epithelial, fallopian tube, or primary peritoneal cavity\n      cancer. Dalantercept may stop the growth of tumor cells by blocking some of the enzymes\n      needed for cell growth. Dalantercept may also stop the growth of tumor cells by blocking\n      blood flow to the tumor."
        }, 
        "brief_title": "Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer", 
        "condition": [
            "Recurrent Fallopian Tube Cancer", 
            "Recurrent Ovarian Epithelial Cancer", 
            "Recurrent Primary Peritoneal Cavity Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Peritoneal Neoplasms", 
                "Fallopian Tube Neoplasms", 
                "Neoplasms, Glandular and Epithelial", 
                "Ovarian Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To estimate the proportion of patients who survive progression-free for at least 6 months\n      and the proportion of patients who have objective tumor response (complete or partial) in\n      patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary\n      peritoneal carcinoma, treated with dalantercept.\n\n      II. To determine the frequency and severity of adverse events associated with treatment with\n      dalantercept as assessed by the Active Version of the National Cancer Institute (NCI) Common\n      Terminology Criteria for Adverse Events (CTCAE).\n\n      SECONDARY OBJECTIVES:\n\n      I. To determine the duration of progression-free survival (PFS) and overall survival (OS).\n\n      TERTIARY OBJECTIVES:\n\n      I. To measure the expression of vascular endothelial growth factor (VEGF), fibroblast growth\n      factor (FGF), platelet-derived growth factor (PDGF), transforming growth factor-beta\n      (TGF-B), activin receptor-like kinase 1 (ALK1), cluster of differentiation 105 (CD105), and\n      other markers via immunohistochemistry (IHC) and determine if there is correlation between\n      expression and clinical response to treatment.\n\n      II. To determine the correlation between ALK1 gene expression, other markers, and clinical\n      response to treatment.\n\n      III. To determine the correlation between concentration of VEGF, bone morphogenetic protein\n      (BMP)9, BMP10, and ALK1 in pre-cycle 1 plasma using an enzyme-linked immunosorbent assay\n      (ELISA), and clinical response to treatment.\n\n      OUTLINE:\n\n      Patients receive dalantercept subcutaneously (SC) on day 1. Courses repeat every 3 weeks in\n      the absence of disease progression or unacceptable toxicity.\n\n      After completion of study treatment, patients are followed up every 3 months for 2 years and\n      then every 6 months for 3 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must have recurrent or persistent epithelial ovarian, fallopian tube, or\n             primary peritoneal carcinoma; histologic documentation of the original primary tumor\n             is required via the pathology report\n\n          -  All patients must have measurable disease as defined by Response Evaluation Criteria\n             in Solid Tumors (RECIST) 1.1; measurable disease is defined as at least one lesion\n             that can be accurately measured in at least one dimension (longest diameter to be\n             recorded); each lesion must be >= 10 mm when measured by computed tomography (CT),\n             magnetic resonance imaging (MRI) or caliper measurement by clinical exam; or >= 20 mm\n             when measured by chest x-ray; lymph nodes must be >= 15 mm in short axis when\n             measured by CT or MRI\n\n          -  Patient must have at least one \"target lesion\" to be used to assess response on this\n             protocol as defined by RECIST 1.1; tumors within a previously irradiated field will\n             be designated as \"non-target\" lesions unless progression is documented or a biopsy is\n             obtained to confirm persistence at least 90 days following completion of radiation\n             therapy\n\n          -  Patients must not be eligible for a higher priority Gynecologic Oncology Group (GOG)\n             protocol, if one exists; in general, this would refer to any active GOG phase III\n             protocol or Rare Tumor protocol for the same patient population\n\n          -  Patients who have received one prior regimen must have a GOG performance status of 0,\n             1, or 2; patients who have received two prior regimens must have a GOG performance\n             status of 0 or 1\n\n          -  Recovery from effects of recent surgery, radiotherapy, or chemotherapy:\n\n               -  Patients should be free of active infection requiring antibiotics (with the\n                  exception of uncomplicated urinary tract infection [UTI])\n\n               -  Any hormonal therapy directed at the malignant tumor must be discontinued at\n                  least one week prior to registration; continuation of hormone replacement\n                  therapy is permitted\n\n               -  Any other prior therapy directed at the malignant tumor, including immunologic\n                  agents, must be discontinued at least three weeks prior to registration; therapy\n                  with nitrosoureas or mitomycin must be discontinued at least six weeks prior to\n                  registration\n\n               -  Any prior radiation therapy must be discontinued at least four weeks prior to\n                  registration\n\n               -  At least 4 weeks must have elapsed since the patient underwent any major surgery\n                  (e.g., major: laparotomy, laparoscopy); there is no delay in treatment for minor\n                  procedures (e.g., central venous access catheter placement)\n\n          -  Prior therapy:\n\n               -  Patients must have had one prior platinum-based chemotherapeutic regimen for\n                  management of primary disease containing carboplatin, cisplatin, or another\n                  organoplatinum compound; this initial treatment may have included\n                  intraperitoneal therapy, consolidation, biologic/targeted (non-cytotoxic) agents\n                  (e.g., bevacizumab) or extended therapy administered after surgical or\n                  non-surgical assessment\n\n               -  Patients are allowed to receive, but are not required to receive, one additional\n                  cytotoxic regimen for management of recurrent or persistent disease\n\n               -  Patients who have received only one prior cytotoxic regimen (platinum-based\n                  regimen for management of primary disease), must have a platinum-free interval\n                  of less than 12 months, or have progressed during platinum-based therapy, or\n                  have persistent disease after a platinum-based therapy\n\n               -  Patients are allowed to receive, but are not required to receive,\n                  biologic/targeted (non-cytotoxic) therapy as part of their primary treatment\n                  regimen\n\n               -  Patients must have NOT received any biologic/targeted (non-cytotoxic) therapy\n                  targeting the VEGF pathway for management of recurrent or persistent disease\n\n               -  For the purposes of this study, poly (ADP-ribose) polymerase (PARP) inhibitors\n                  will be considered \"cytotoxic\"; patients are allowed to receive, but are not\n                  required to receive, PARP inhibitors for management of primary or\n                  recurrent/persistent disease (either alone or in combination with cytotoxic\n                  chemotherapy); PARP inhibitors will NOT count as a prior regimen when given\n                  alone\n\n          -  Absolute neutrophil count (ANC) greater than or equal to 1,500/mcl\n\n          -  Platelets greater than or equal to100,000/mcl\n\n          -  Hemoglobin greater than or equal to 9 g/dl\n\n          -  Creatinine less than or equal to 1.5 x institutional upper limit normal (ULN)\n\n          -  Sodium greater than or equal to 130 mEq/L (CTCAE version 4 [v. 4], grade 0 or 1)\n\n          -  Urine protein should be screened by urinalysis; if protein is 2+ or higher, 24-hour\n             urine protein should be obtained and the level should be < 1000 mg (< 1.0 g/24 hrs)\n             for patient enrollment\n\n          -  Bilirubin less than or equal to 1.5 x ULN\n\n          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) less than or\n             equal to 3 x ULN\n\n          -  Alkaline phosphatase less than or equal to 3 x ULN\n\n          -  Albumin greater than or equal to 3 (CTCAE v. 4, grade 0 or 1)\n\n          -  Prothrombin time (PT) such that international normalized ratio (INR) is less than or\n             equal to 1.5 x ULN (or an in-range INR, usually between 2 and 3, if a patient is on a\n             stable dose of therapeutic warfarin) and partial thromboplastin time (PTT) less than\n             or equal to 1.5 x ULN\n\n          -  Left ventricular ejection fraction (LVEF) greater than 50% (measured by\n             echocardiogram or MUGA [multi-gated acquisition] scan)\n\n          -  Patients must have signed an approved informed consent and authorization permitting\n             release of personal health information\n\n          -  Patients must meet pre-entry requirements\n\n          -  Patients of childbearing potential must have a negative pregnancy test prior to the\n             study entry and be practicing an effective form of contraception\n\n        Exclusion Criteria:\n\n          -  Patients who have had previous treatment with dalantercept or any other anti-ALK1\n             (activin receptor-like kinase 1) agent\n\n          -  Patients with a history of other invasive malignancies, with the exception of\n             non-melanoma skin cancer and other specific malignancies, are excluded if there is\n             any evidence of other malignancy being present within the last three years; patients\n             are also excluded if their previous cancer treatment contraindicates this protocol\n             therapy\n\n          -  Patients who have received prior radiotherapy to any portion of the abdominal cavity\n             or pelvis OTHER THAN for the treatment of ovarian, fallopian tube, or primary\n             peritoneal cancer within the last three years are excluded; prior radiation for\n             localized cancer of the breast, head and neck, or skin is permitted, provided that it\n             was completed more than three years prior to registration, and the patient remains\n             free of recurrent or metastatic disease\n\n          -  Patients who have received prior chemotherapy for any abdominal or pelvic tumor OTHER\n             THAN for the treatment of ovarian, fallopian tube, or primary peritoneal cancer\n             within the last three years are excluded; patients may have received prior adjuvant\n             chemotherapy for localized breast cancer, provided that it was completed more than\n             three years prior to registration, and that the patient remains free of recurrent or\n             metastatic disease\n\n          -  Patients with a past history of primary endometrial cancer are excluded unless all of\n             the following conditions are met: stage not greater than I-B; no more than\n             superficial myometrial invasion, without vascular or lymphatic invasion; no poorly\n             differentiated subtypes, including papillary serious, clear cell or other\n             International Federation of Gynecology and Obstetrics (FIGO) grade 3 lesions\n\n          -  Patients with history or evidence upon physical exam of central nervous system (CNS)\n             disease, including primary brain tumor, seizures not controlled with standard medical\n             therapy or any brain metastases\n\n          -  Serious or non-healing wound, ulcer or bone fracture\n\n          -  History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess\n             within 6 months\n\n          -  Patients requiring parenteral hydration or parenteral/total parenteral nutrition\n\n          -  Patients with:\n\n               -  Active bleeding (e.g., active hemoptysis, defined as bright red blood of greater\n                  than or equal to 1/2 teaspoon [2.5 ml] in any 24 hour period within 2 weeks\n                  prior to registration or gastrointestinal bleeding within 3 months prior to\n                  registration)\n\n               -  Hereditary hemorrhagic telangiectasia (HHT)\n\n               -  Platelet function abnormality\n\n               -  Autoimmune or hereditary hemolysis\n\n               -  Coagulopathy\n\n               -  Tumor involving major vessels (defined as any lesion invading or abutting the\n                  wall [i.e., no fat plane evident] of major blood vessels as assessed by CT or\n                  MRI)\n\n          -  Patients receiving treatment with full dose aspirin (325mg oral daily), clopidogrel\n             (Plavix) or dabigatran (Pradaxa)\n\n          -  Patients with peripheral edema greater than or equal to grade 1, within 4 weeks of\n             registration\n\n          -  Patients with clinically significant cardiovascular disease:\n\n               -  Uncontrolled hypertension, defined as systolic > 150 mm Hg or diastolic > 90 mm\n                  Hg despite antihypertensive medications\n\n               -  Evidence of hypertrophic cardiomyopathy\n\n               -  New York Heart Association (NYHA) class II or greater congestive heart failure\n                  (CHF)\n\n               -  Any of the following within 6 months prior to study registration:\n\n                    -  Bypass surgery\n\n                    -  Stent placement\n\n                    -  Myocardial infarction\n\n                    -  Acute coronary syndrome/unstable angina\n\n                    -  Hospitalization for CHF\n\n               -  Serious cardiac arrhythmia requiring medication; this does not include\n                  asymptomatic, atrial fibrillation with controlled ventricular rate\n\n               -  Prolonged corrected QT (QTc) interval > 450 ms\n\n               -  Prior anthracycline cumulative dose > 450 mg/m^2\n\n          -  History of severe (National Cancer Institute-Common Terminology Criteria for Adverse\n             Events [NCI-CTCAE] v.4.0 >= grade 3) allergic or anaphylactic reaction or\n             hypersensitivity to recombinant proteins or Tris buffered saline\n\n          -  Patients who are pregnant or nursing\n\n          -  History of syndrome of inappropriate antidiuretic hormone secretion (SIADH)\n\n          -  Patients who have undergone a therapeutic paracentesis within 4 weeks of registration\n\n          -  Known history of positive hepatitis C virus (HCV) antibody, hepatitis B virus (HBV)\n             surface antigen (HBsAg) or HBV core antibody, or human immunodeficiency virus (HIV)\n             antibody results\n\n          -  Clinically significant active pulmonary risk including pulmonary hypertension,\n             pulmonary embolism, or history of pulmonary edema"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "56", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 30, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01720173", 
            "org_study_id": "GOG-0170R", 
            "secondary_id": [
                "NCI-2012-01936", 
                "NSC #757172", 
                "CDR0000742512", 
                "GOG-0170R", 
                "GOG-0170R", 
                "U10CA027469"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment (dalantercept)", 
                "description": "Given SC", 
                "intervention_name": "dalantercept", 
                "intervention_type": "Biological", 
                "other_name": [
                    "ACE-041", 
                    "activin receptor-like kinase 1 inhibitor ACE-041", 
                    "ALK1-Fc fusion protein ACE-041"
                ]
            }, 
            {
                "arm_group_label": "Treatment (dalantercept)", 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 25, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Fort Collins", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80524"
                    }, 
                    "name": "Poudre Valley Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hartford", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06102"
                    }, 
                    "name": "Hartford Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Britain", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06050"
                    }, 
                    "name": "The Hospital of Central Connecticut"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lewes", 
                        "country": "United States", 
                        "state": "Delaware", 
                        "zip": "19958"
                    }, 
                    "name": "Beebe Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Newark", 
                        "country": "United States", 
                        "state": "Delaware", 
                        "zip": "19718"
                    }, 
                    "name": "Christiana Care Health System-Christiana Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Savannah", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "31405"
                    }, 
                    "name": "Saint Joseph's-Candler Health System"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Decatur", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "62526"
                    }, 
                    "name": "Decatur Memorial Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Iowa City", 
                        "country": "United States", 
                        "state": "Iowa", 
                        "zip": "52242"
                    }, 
                    "name": "University of Iowa Hospitals and Clinics"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Maine", 
                        "zip": "04102"
                    }, 
                    "name": "Maine Medical Center-Bramhall Campus"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Elkton MD", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21921"
                    }, 
                    "name": "Union Hospital of Cecil County"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Worcester", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "01605"
                    }, 
                    "name": "University of Massachusetts Memorial Health Care"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kalamazoo", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "49007"
                    }, 
                    "name": "West Michigan Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jackson", 
                        "country": "United States", 
                        "state": "Mississippi", 
                        "zip": "39216"
                    }, 
                    "name": "University of Mississippi Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saint Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63110"
                    }, 
                    "name": "Washington University School of Medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Omaha", 
                        "country": "United States", 
                        "state": "Nebraska", 
                        "zip": "68114"
                    }, 
                    "name": "Nebraska Methodist Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Albuquerque", 
                        "country": "United States", 
                        "state": "New Mexico", 
                        "zip": "87106"
                    }, 
                    "name": "University of New Mexico"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10065"
                    }, 
                    "name": "Memorial Sloan-Kettering Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44106"
                    }, 
                    "name": "Case Western Reserve University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44111"
                    }, 
                    "name": "Cleveland Clinic Cancer Center/Fairview Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44195"
                    }, 
                    "name": "Cleveland Clinic Foundation"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mayfield Heights", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44124"
                    }, 
                    "name": "Hillcrest Hospital Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mentor", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44060"
                    }, 
                    "name": "Lake University Ireland Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oklahoma City", 
                        "country": "United States", 
                        "state": "Oklahoma", 
                        "zip": "73104"
                    }, 
                    "name": "University of Oklahoma Health Sciences Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Abington", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19001"
                    }, 
                    "name": "Abington Memorial Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19111-2497"
                    }, 
                    "name": "Fox Chase Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19103"
                    }, 
                    "name": "Gynecologic Oncology Group"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19107"
                    }, 
                    "name": "Thomas Jefferson University Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Providence", 
                        "country": "United States", 
                        "state": "Rhode Island", 
                        "zip": "02905"
                    }, 
                    "name": "Women and Infants Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sioux Falls", 
                        "country": "United States", 
                        "state": "South Dakota", 
                        "zip": "57105"
                    }, 
                    "name": "CCOP Sioux Community Cancer Consortium"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sioux Falls", 
                        "country": "United States", 
                        "state": "South Dakota", 
                        "zip": "57104"
                    }, 
                    "name": "Sanford Cancer Center-Oncology Clinic"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sioux Falls", 
                        "country": "United States", 
                        "state": "South Dakota", 
                        "zip": "57105"
                    }, 
                    "name": "Sanford Clinic Women's Health"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sioux Falls", 
                        "country": "United States", 
                        "state": "South Dakota", 
                        "zip": "57117-5134"
                    }, 
                    "name": "Sanford USD Medical Center - Sioux Falls"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98133"
                    }, 
                    "name": "Northwest Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98104"
                    }, 
                    "name": "Pacific Gynecology Specialists"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98109"
                    }, 
                    "name": "Seattle Cancer Care Alliance"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98195"
                    }, 
                    "name": "University of Washington Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Green Bay", 
                        "country": "United States", 
                        "state": "Wisconsin", 
                        "zip": "54301"
                    }, 
                    "name": "Saint Vincent Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Green Bay", 
                        "country": "United States", 
                        "state": "Wisconsin", 
                        "zip": "54303"
                    }, 
                    "name": "Green Bay Oncology Limited at Saint Mary's Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Green Bay", 
                        "country": "United States", 
                        "state": "Wisconsin", 
                        "zip": "54301-3526"
                    }, 
                    "name": "Green Bay Oncology at Saint Vincent Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Manitowoc", 
                        "country": "United States", 
                        "state": "Wisconsin", 
                        "zip": "54221"
                    }, 
                    "name": "Holy Family Memorial Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Marinette", 
                        "country": "United States", 
                        "state": "Wisconsin", 
                        "zip": "54143"
                    }, 
                    "name": "Bay Area Medical Center"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A PHASE II EVALUATION OF DALANTERCEPT (NSC #757172, IND #116598), A NOVEL SOLUBLE RECOMBINANT ACTIVIN RECEPTOR-LIKE KINASE 1 (ALK-1) INHIBITOR RECEPTOR-FUSION PROTEIN, IN THE TREATMENT OF PERSISTENT OR RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CARCINOMA", 
        "overall_official": {
            "affiliation": "Gynecologic Oncology Group", 
            "last_name": "Robert Burger", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Suspended", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Proportion of patients who survive progression-free (without non-protocol therapy) for at least 6 months after study entry or have objective tumor response (complete or partial)", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Frequency and severity of adverse effects as assessed by CTCAE", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 5 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01720173"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Will be characterized with Kaplan-Meier plots and estimates of the median time until progression.", 
                "measure": "Duration of progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "Time from study entry to time of progression or death, whichever occurs first, assessed up to 5 years"
            }, 
            {
                "description": "Will be characterized with Kaplan-Meier plots and estimates of the median time until death.", 
                "measure": "Duration of overall survival", 
                "safety_issue": "No", 
                "time_frame": "From study entry to time of death or the date of last contact, assessed up to 5 years"
            }
        ], 
        "source": "Gynecologic Oncology Group", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Gynecologic Oncology Group", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014", 
        "why_stopped": "Temporarily Closed to Accrual"
    }
}